[Endocrine therapy of causation: role of aromatase inhibitors in breast cancer]

Tumori. 2003 Nov-Dec;89(6):21-8. doi: 10.1177/030089160308900622.
[Article in Italian]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aromatase Inhibitors*
  • Breast Neoplasms / drug therapy*
  • Controlled Clinical Trials as Topic
  • Cross-Over Studies
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Estrogen Receptor Modulators / therapeutic use
  • Female
  • Humans
  • Letrozole
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Nitriles / therapeutic use
  • Survival Analysis
  • Tamoxifen / therapeutic use
  • Treatment Outcome
  • Triazoles / therapeutic use

Substances

  • Antineoplastic Agents
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Enzyme Inhibitors
  • Estrogen Receptor Modulators
  • Nitriles
  • Triazoles
  • Tamoxifen
  • Letrozole